MeMed

Rapid Infection Diagnostics | Bacterial vs Viral Test

Haifa, Israel · Founded 2009 · $181.1M raised

Headquarters
Haifa
Employees
51–200
Founded
2009
Business Model
B2B
Website
me-med.com
Total Funding
$181.1M
Last Round
$14.1M Growth EquityMay 2026
Rounds
4

About

MeMed applies machine learning to translate complex immune-system signaling into actionable diagnostic insights for infectious diseases and inflammatory disorders. Its FDA-cleared MeMed BV host-immune response assay distinguishes bacterial from viral infections in 15 minutes. The compact MeMed Key immunoassay platform performs sensitive, rapid, multiplexed protein measurements, and together the products help physicians manage patients with acute infections.

Summary

MeMed is a Biotech company based in Haifa, Israel, founded in 2009. It has raised $181.1M in total across 4 rounds, most recently a $14.1M Growth Equity round in May 2026. Investors include DGF Investimentos, BridgeOne and U.S. Department of Defense.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Growth EquityGrowth EquityMay 2026
$14.1M

Sign up to see all 4 rounds

Growth Equity through Series E — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MeMed on Indexed.vc
<a href="https://indexed.vc/companies/memed"><img src="https://indexed.vc/api/badge/company/memed" alt="MeMed on Indexed.vc" width="260" height="76" /></a>